Literature DB >> 1359669

Association of HLA-B51 and lack of association of class II alleles with Behçet's disease.

N Mizuki1, S Ohno, H Tanaka, K Sugimura, T Seki, N Mizuki1, J Kera, G Inaba, K Tsuji, H Inoko.   

Abstract

Eighty-one Behcet's disease patients have been studied for HLA association by HLA-DRB1, -DQA1, -DQB1 and -DPB1 genotyping with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique and for NcoI RFLP in the tumor-necrosis factor (TNF beta) gene by Southern hybridization in addition to serological typing. In serological typing, the frequency of HLA-B51 was significantly increased in the patients. In PCR genotyping, there was a significant increase in the HLA-DRB1*0802, DQA1*0301 and DQB1*0303 alleles, whereas the frequencies of DRB1*1502, DQA1*0103, DQA1*0101, DQB1*0601 and DQB1*0501 showed a significant decrease in the patients. No significant difference was observed in any HLA-DPB1 alleles. Among them, B51 was found to be a genetic marker most strongly associated with Behcet's disease (p less than 0.00005, chi 2 = 46.47, pc[corrected p] less than 0.005). The positive and negative associations of class II alleles with the disease can be explained by linkage disequilibrium with B51, and do not reach statistical significance by the corrected p-value test. In NcoI RFLP typing in the TNF beta gene, 250 kb centromeric of the HLA-B gene, the frequency of a 5.5 kb fragment was considerably decreased in the patients when compared to the controls, although the decrease was not statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359669     DOI: 10.1111/j.1399-0039.1992.tb01953.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  9 in total

1.  Primary association of HLA-B51 with Behçet's disease in Ireland.

Authors:  D J Kilmartin; A Finch; R W Acheson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

2.  Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies.

Authors:  Owen D Solberg; Steven J Mack; Alex K Lancaster; Richard M Single; Yingssu Tsai; Alicia Sanchez-Mazas; Glenys Thomson
Journal:  Hum Immunol       Date:  2008-06-09       Impact factor: 2.850

3.  The complete genomic sequence of 424,015 bp at the centromeric end of the HLA class I region: gene content and polymorphism.

Authors:  T Guillaudeux; M Janer; G K Wong; T Spies; D E Geraghty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

4.  Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease.

Authors:  S Lee; D Bang; Y H Cho; E S Lee; S Sohn
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

5.  Association of the MIC-A gene and HLA-B51 with Behçet's disease in Arabs and non-Ashkenazi Jews in Israel.

Authors:  R Cohen; S Metzger; M Nahir; T Chajek-Shaul
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

6.  A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on behçet's disease in Japan.

Authors:  M Nishiyama; K Nakae; S Yukawa; T Hashimoto; G Inaba; M Mochizuki; T Sakane
Journal:  Environ Health Prev Med       Date:  1999-10       Impact factor: 3.674

7.  Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease.

Authors:  Aşkin Ateş; Gülay Kinikli; Nurşen Düzgün; Murat Duman
Journal:  Rheumatol Int       Date:  2005-05-05       Impact factor: 2.631

8.  Neurological manifestations of Behçet's disease in Japan: a study of 54 patients.

Authors:  Haruko Ideguchi; Akiko Suda; Mitsuhiro Takeno; Yohei Kirino; Atsushi Ihata; Atsuhisa Ueda; Shigeru Ohno; Yasuhisa Baba; Yoshiyuki Kuroiwa; Yoshiaki Ishigatsubo
Journal:  J Neurol       Date:  2010-02-03       Impact factor: 4.849

9.  Animal Models in Behçet's Disease.

Authors:  Ozlem Yildirim
Journal:  Patholog Res Int       Date:  2012-02-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.